Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

被引：2
作者：
Revuelta-Herrero, J. L. [1 ]
Gimenez-Manzorro, A. [1 ]
Matilla-Pena, A.
Herranz-Alonso, A. [1 ,2 ]
Sanjurjo-Saez, M. [1 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Pharm Dept, IiSGM, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Gastroenterol Dept, IiSGM, Madrid, Spain
来源：
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2018年 / 43卷 / 06期
关键词：
antiviral agents; drug interaction; hepatitis C; hepatocellular carcinoma; sorafenib; HEPATOCELLULAR-CARCINOMA; EVENTS; HCC;
D O I：
10.1111/jcpt.12727
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
What is known and objective No studies have evaluated the use of sorafenib with the direct-acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). Case summaryWhat is new and conclusionThree hepatitis C virus genotype 1b-infected patients with well-preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24weeks was achieved, and no tumour recurrences were found. The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective.
引用
收藏
页码：906 / 909
页数：4
相关论文
共 50 条
  • [31] Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
    Di Costanzo, Giovan Giuseppe
    Tortora, Raffaella
    Iodice, Luca
    Lanza, Alfonso Galeota
    Lampasi, Filippo
    Tartaglione, Maria Teresa
    Picciotto, Francesco Paolo
    Mattera, Silvana
    De Luca, Massimo
    DIGESTIVE AND LIVER DISEASE, 2012, 44 (09) : 788 - 792
  • [32] Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus
    Stauber, Rudolf E.
    Fauler, Guenter
    Rainer, Florian
    Leber, Bettina
    Posch, Andreas
    Streit, Andrea
    Spindelboeck, Walter
    Stadlbauer, Vanessa
    Kessler, Harald H.
    Mangge, Harald
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (21-22) : 848 - 851
  • [33] Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
    Grebely, Jason
    Conway, Brian
    Cunningham, Evan B.
    Fraser, Chris
    Moriggia, Alberto
    Gane, Ed
    Stedman, Catherine
    Cooper, Curtis
    Castro, Erika
    Schmid, Patrick
    Petoumenos, Kathy
    Hajarizadeh, Behzad
    Marks, Phillipa
    Erratt, Amanda
    Dalgard, Olav
    Lacombe, Karine
    Feld, Jordan J.
    Bruneau, Julie
    Daulouede, Jean-Pierre
    Powis, Jeff
    Bruggmann, Philip
    Matthews, Gail V.
    Kronborg, Ian
    Shaw, David
    Dunlop, Adrian
    Hellard, Margaret
    Applegate, Tanya L.
    Crawford, Sione
    Dore, Gregory J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 62 : 94 - 103
  • [34] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
    Khatri, Amit
    Mensing, Sven
    Podsadecki, Thomas
    Awni, Walid
    Menon, Rajeev
    Dutta, Sandeep
    CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 625 - 635
  • [35] Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir plus dasabuvir plus ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
    Babic, Jasmina Simonovic
    Bojovic, Ksenija
    Fabri, Milotka
    Cvejic, Tatjana
    Svorcan, Petar
    Nozic, Darko
    Jovanovic, Maja
    Skrbic, Ranko
    Stojiljkovic, Milos P.
    Mijailovic, Zeljko
    VOJNOSANITETSKI PREGLED, 2019, 76 (05) : 531 - 536
  • [36] Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
    Martinello, M.
    Bhagani, S.
    Gane, E.
    Orkin, C.
    Cooke, G.
    Dore, G. J.
    Petoumenos, K.
    Applegate, T. L.
    Tu, E.
    Marks, P.
    Pagani, N.
    Grebely, J.
    Nelson, M.
    Matthews, G. V.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (10) : 1180 - 1188
  • [37] Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis
    Wedemeyer, H.
    Craxi, A.
    Zuckerman, E.
    Dieterich, D.
    Flisiak, R.
    Roberts, S. K.
    Pangerl, A.
    Zhang, Z.
    Martinez, M.
    Bao, Y.
    Calleja, J. -L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (11) : 936 - 943
  • [38] Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
    Atsukawa, Masanori
    Tsubota, Akihito
    Koushima, Yohei
    Ikegami, Tadashi
    Watanabe, Kouji
    Shimada, Noritomo
    Sato, Shinichi
    Kato, Keizo
    Abe, Hiroshi
    Okubo, Tomomi
    Arai, Taeang
    Itokawa, Norio
    Kondo, Chisa
    Mikami, Shigeru
    Asano, Toru
    Chuganji, Yoshimichi
    Matsuzaki, Yasushi
    Iwakiri, Katsuhiko
    HEPATOLOGY RESEARCH, 2017, 47 (13) : 1429 - 1437
  • [39] Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
    Hussaini, Trana
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2016, 8 : 61 - 68
  • [40] Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1-final results of the REV1TAL study
    Lubel, John
    Strasser, Simone
    Stuart, Katherine A.
    Dore, Gregory
    Thompson, Alexander
    Pianko, Stephen
    Bollipo, Steven
    Mitchell, Joanne L.
    Fragomeli, Vincenzo
    Jones, Tracey
    Chivers, Sarah
    Gow, Paul
    Iser, David
    Levy, Miriam
    Tse, Edmund
    Gazzola, Alessia
    Cheng, Wendy
    Nazareth, Saroj
    Galhenage, Sam
    Wade, Amanda
    Weltman, Martin
    Wigg, Alan
    MacQuillan, Gerry
    Sasadeusz, Joe
    George, Jacob
    Zekry, Amany
    Roberts, Stuart K.
    ANTIVIRAL THERAPY, 2017, 22 (08) : 699 - 710
12345